1-7 of 7
Yan Luo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Nizar J Bahlis, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Niels Abildgaard, Jacob Laubach, Vincent Ribrag, Peter M. Voorhees, Xifeng Wang, Orlando Bueno, Yan Luo, Jeremy A Ross, Jonathan L. Kaufman
Journal: Blood
Blood (2023) 142 (Supplement 1): 338.
https://doi.org/10.1182/blood-2023-180766
Published: 2023
Journal Articles

Real-World Treatment Patterns and Outcomes of Daratumumab Retreatment in Multiple Myeloma in the United States

Allicia Girvan, Junhua Yu, Nnadozie Emechebe, Rajesh Kamalakar, Yan Luo
Journal: Blood
Blood (2022) 140 (Supplement 1): 5266–5267.
https://doi.org/10.1182/blood-2022-158270
Published: 2022
Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7261–7263.
https://doi.org/10.1182/blood-2022-163809
Published: 2022
Journal Articles

Granulocyte Colony-Stimulating Factor Impairs Engraftment of CRISPR-Cas9 Gene Edited Human Hematopoietic Stem Cells By Exacerbating p53 Mediated DNA Damage Response

Daisuke Araki, Vicky Chen, Neelam Redekar, Poching Li, Yan Luo, Yuesheng Li, Andre Larochelle
Journal: Blood
Blood (2022) 140 (Supplement 1): 307–308.
https://doi.org/10.1182/blood-2022-158511
Published: 2022
Journal Articles

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Mohamed A Badawi, Benjamin Engelhardt, Jesus Badillo, Ahmed Abbas Suleiman, Leanne Lash Fleming, Yan Luo, Jonathan L. Kaufman, Nizar Jacques Bahlis, Rajeev Menon, Ahmed Hamed Salem
Journal: Blood
Blood (2022) 140 (Supplement 1): 10122–10123.
https://doi.org/10.1182/blood-2022-166429
Published: 2022
Journal Articles

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis
Journal: Blood
Blood (2021) 138 (Supplement 1): 817.
https://doi.org/10.1182/blood-2021-146043
Published: 2021
Journal Articles

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Nizar J. Bahlis, Jonathan L. Kaufman, Rachid Baz, Hang Quach, Shir-Jing Ho, Annette J. Vangsted, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Orlando F. Bueno, Yan Luo, Christine Mantis, Deeksha Vishwamitra, Jeremy A. Ross, Simon J Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 1633.
https://doi.org/10.1182/blood-2021-146012
Published: 2021